List of Excipients in Branded Drug BIKTARVY

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	50090-6247	CELLULOSE, MICROCRYSTALLINE	2036-11-08
A-S Medication Solutions	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	50090-6247	CROSCARMELLOSE SODIUM	2036-11-08
A-S Medication Solutions	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	50090-6247	FERRIC OXIDE RED	2036-11-08
A-S Medication Solutions	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	50090-6247	FERROSOFERRIC OXIDE	2036-11-08
A-S Medication Solutions	BIKTARVY	bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate	50090-6247	MAGNESIUM STEARATE	2036-11-08

Biktarvy Excipient Strategy and Commercial Opportunities

Last updated: September 1, 2026

Biktarvy is a once-daily, fixed-dose HIV-1 tablet containing bictegravir, emtricitabine, and tenofovir alafenamide. Its excipient strategy prioritizes rapid disintegration, chemical stability, compact tablet size, film-coating performance, and scalable high-volume manufacturing. The strongest commercial opportunities are in qualified excipient supply, direct-compression platforms, pediatric and geriatric dosage forms, regional manufacturing, and lifecycle formulations rather than in simple substitution of listed inactive ingredients.

What excipients are used in Biktarvy?

Biktarvy uses a conventional immediate-release tablet platform with a film coating. The FDA prescribing information identifies the following inactive ingredients.[1]

Component	Function in the formulation
Croscarmellose sodium	Superdisintegrant that promotes tablet breakup after ingestion
Magnesium stearate	Lubricant that reduces friction during compression and ejection
Microcrystalline cellulose	Diluent, dry binder, and compression aid
Sodium lauryl sulfate	Wetting agent that supports powder wetting and dissolution
Iron oxide red	Colorant in the film coating
Polyethylene glycol	Plasticizer and coating aid
Polyvinyl alcohol	Film-forming polymer
Talc	Anti-tacking and coating-process aid
Titanium dioxide	Opacifier and white pigment

The tablet contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. Biktarvy is supplied as a pink, capsule-shaped, film-coated tablet.[1]

The formulation has a practical excipient architecture. Microcrystalline cellulose provides bulk and compressibility, croscarmellose sodium supports rapid disintegration, and sodium lauryl sulfate improves wetting of hydrophobic drug substances. Magnesium stearate enables high-speed tableting but requires controlled blending because excess lubrication can reduce tablet strength and slow dissolution.

Why is Biktarvy’s excipient strategy commercially important?

Biktarvy combines three active pharmaceutical ingredients with different physicochemical and dose characteristics. The formulation must manage:

• A low-dose integrase inhibitor, bictegravir
• A higher-dose nucleoside reverse transcriptase inhibitor, emtricitabine
• A low-dose prodrug, tenofovir alafenamide
• Multiple active ingredients with different particle properties
• A small, swallowable once-daily tablet
• Stability requirements for long shelf life
• Consistent dissolution across commercial manufacturing sites

The excipients do not provide the primary intellectual-property barrier. Their commercial value comes from enabling reproducible manufacture and maintaining the drug product’s quality profile. For a high-volume product, small improvements in blend uniformity, tablet tensile strength, coating speed, yield, or dissolution control can create material manufacturing savings.

What formulation functions do the Biktarvy excipients perform?

Microcrystalline cellulose and croscarmellose sodium

Microcrystalline cellulose is likely the principal structural excipient. It supports direct compression and helps accommodate low-dose actives that must be distributed uniformly through the blend. Croscarmellose sodium counterbalances the compact tablet structure by promoting rapid water uptake and tablet breakup.

This combination is widely used in immediate-release products. The commercial opportunity is therefore not basic excipient novelty. It is grade selection, particle-size control, moisture management, and supplier qualification.

Different grades of microcrystalline cellulose can materially affect:

• Flowability
• Compactability
• Tablet hardness
• Ejection force
• Blend segregation
• Disintegration time
• Dissolution variability

Croscarmellose sodium can show similar grade-dependent behavior. Fiber morphology, swelling capacity, particle size, and moisture content influence tablet performance.

Sodium lauryl sulfate

Sodium lauryl sulfate is a surfactant and wetting agent. It can improve dissolution when one or more active ingredients have limited wettability. Its level must remain tightly controlled because surfactant concentration can affect dissolution, disintegration, powder flow, and compatibility with other formulation components.

A supplier with strong pharmaceutical-grade documentation, low impurity levels, controlled residual solvents, and consistent surface-active behavior has a stronger position than a commodity supplier.

Magnesium stearate

Magnesium stearate supports high-speed compression and reduces sticking and ejection force. It is also one of the formulation’s key process-risk excipients. Over-lubrication can create a hydrophobic coating around particles, reducing tablet strength and slowing dissolution.

The main commercial opportunities involve:

• Controlled specific surface area
• Consistent fatty-acid composition
• Low variability in lubrication performance
• Improved blending protocols
• Continuous manufacturing compatibility
• Low-metal and low-peroxide grades

Film-coating excipients

The polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, and iron oxide red coating system provides protection, identification, swallowability, and visual uniformity. The coating also allows control of tablet appearance and can reduce handling damage.

Commercial value exists in ready-to-use coating systems that reduce:

• Coating development time
• Spray-process optimization
• Color variation
• Batch rejection risk
• Cleaning and changeover time
• Dependence on multiple raw-material suppliers

What excipient suppliers could target Biktarvy manufacturing?

The most realistic targets are qualified suppliers that can offer equivalent or superior performance without changing the drug product’s critical quality attributes.

High-value supplier propositions

Opportunity	Commercial rationale	Main barrier
Direct-compression microcrystalline cellulose	Improves flow and compactability	Requires comparative process and dissolution data
High-performance croscarmellose sodium	Supports rapid disintegration at low use levels	Must preserve tablet robustness
Pharmaceutical-grade sodium lauryl sulfate	Improves wetting and dissolution consistency	Tight impurity and particle-property controls
Low-variability magnesium stearate	Reduces lubrication-related dissolution risk	Supplier change requires extensive comparability
Ready-to-use film coating	Simplifies coating operations	Color and appearance must remain within specification
Continuous-manufacturing excipient grades	Supports process intensification	Requires advanced flow and residence-time data
Low-moisture excipients	Protects stability of sensitive active ingredients	Packaging and storage controls increase cost
Regionally manufactured excipients	Reduces freight and supply-chain concentration	Regulatory qualification remains necessary

A supplier cannot assume that a compendial match is sufficient. Pharmaceutical excipients are often controlled through functional specifications that extend beyond USP, Ph. Eur., or other monograph requirements. These can include particle-size distribution, bulk density, tapped density, moisture, microbial limits, elemental impurities, and performance in the finished dosage form.

What formulation patents protect Biktarvy?

Biktarvy’s principal protection is associated with its active ingredients, combination, manufacturing processes, and drug-product regulatory exclusivity. The listed excipients are established pharmaceutical materials and generally do not create a strong standalone exclusivity position.

A competitor could use different excipients while maintaining the same active ingredients and dosage strengths. That makes excipient substitution a potential route for an abbreviated new drug application if the applicant can demonstrate pharmaceutical equivalence, bioequivalence, and acceptable product quality.

The practical formulation barriers are more likely to involve:

• The specific combination of three active ingredients
• Bictegravir-related composition and process patents
• Drug-product manufacturing controls
• Stability and impurity control
• Tablet size and mechanical properties
• Bioequivalence across a multi-active product
• Manufacturing know-how not fully disclosed in public filings

The FDA Orange Book should be reviewed for the current listed patents and regulatory exclusivities before making an entry or licensing decision.[2] Public patent records should be checked separately because not every manufacturing or process right will necessarily appear as an Orange Book drug-product listing.

When does Biktarvy lose exclusivity?

Biktarvy’s market-exclusivity analysis has several layers:

1. FDA regulatory exclusivity for the fixed-dose combination
2. Patents covering bictegravir
3. Patents covering the combination or drug product
4. Manufacturing and process patents
5. Pediatric exclusivity, if applicable
6. Patent-term adjustments or extensions
7. Paragraph IV challenges and litigation outcomes

A single “Biktarvy expiration date” is therefore incomplete. The earliest legally available generic launch date depends on the enforceable patent claims, statutory stays, settlement terms, and any litigation judgment.

The FDA’s Orange Book provides the principal public source for listed patent claims and expiration information.[2] Patent expiration dates should be reconciled against USPTO records and court dockets before valuation.

Are there Paragraph IV challenges to Biktarvy?

A generic applicant may file a Paragraph IV certification against an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or will not be infringed. For Biktarvy, a challenge could target:

• Bictegravir composition claims
• Combination-product claims
• Dosage-form claims
• Use claims
• Manufacturing claims, where relevant to the approved product

A Paragraph IV filing can trigger litigation and, under the Hatch-Waxman framework, a statutory stay of FDA approval for up to 30 months in defined circumstances.[3] The business effect depends on whether the challenged patent is central to commercial launch or only covers a narrow use or process.

No commercial conclusion should be based solely on the existence of a Paragraph IV notice. The relevant questions are claim scope, Orange Book listing status, infringement risk, litigation timing, and settlement restrictions.

What commercial opportunities exist in Biktarvy lifecycle management?

Pediatric and swallowing-friendly formulations

A major lifecycle opportunity is a formulation for patients who cannot reliably swallow the existing tablet. Potential approaches include:

• Smaller tablets
• Dispersible tablets
• Granules
• Oral powders
• Carefully designed oral suspensions

Any new dosage form must preserve exposure to all three active ingredients. Bictegravir and tenofovir alafenamide create particular development challenges because excipient changes can alter wetting, dissolution, and absorption.

Fixed-dose combination manufacturing platforms

The Biktarvy architecture may support development platforms for other antiretroviral combinations. Commercial value can arise from manufacturing systems that handle multiple low-dose and high-dose actives with minimal segregation.

Relevant technologies include:

• Ordered mixing
• Dry granulation
• Roller compaction
• Continuous blending
• Process analytical technology
• Near-infrared blend uniformity monitoring
• Low-shear lubrication

These technologies can reduce batch losses and improve scale-up performance.

Regional supply and dual sourcing

Biktarvy’s sales scale creates demand for secure excipient supply. Suppliers with manufacturing in North America, Europe, India, or other major pharmaceutical regions can compete on supply resilience, not only price.

A credible dual-source strategy requires:

• Comparable excipient functionality
• Consistent certificates of analysis
• Change-control discipline
• Audit readiness
• Comparable packaging
• Stability data
• Validated analytical methods
• Regulatory documentation for post-approval changes

Film-coating systems

Ready-to-use coating systems can reduce development and manufacturing complexity. A supplier may create value by offering a coating that matches the existing color, gloss, opacity, adhesion, and mechanical protection while shortening process-development time.

The opportunity is strongest where a contract manufacturer wants to qualify a second source or move production to a different facility.

How does Biktarvy compare with competing HIV regimens?

Biktarvy competes with other single-tablet or once-daily antiretroviral regimens, including Genvoya, Triumeq, Dovato, and Odefsey. Their excipient opportunities differ because each product has a distinct active-ingredient combination and dosage form.

Product	Active ingredients	Formulation implication
Biktarvy	Bictegravir, emtricitabine, tenofovir alafenamide	Three-active immediate-release tablet with high commercial volume
Genvoya	Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide	Four-active combination with booster-related formulation requirements
Triumeq	Dolutegravir, abacavir, lamivudine	Different active load and excipient-performance profile
Dovato	Dolutegravir, lamivudine	Lower active count may simplify blend uniformity and tablet design
Odefsey	Emtricitabine, rilpivirine, tenofovir alafenamide	Food-effect and dissolution considerations differ

Biktarvy’s commercial advantage is its broad use as a complete once-daily regimen and its high product sales. Gilead reported Biktarvy product sales of approximately $11.9 billion in 2023, making supply continuity and manufacturing efficiency commercially significant.[4]

What generic entry risks exist for Biktarvy?

The principal generic risks are delayed rather than immediate substitution risks. A generic entrant must address:

• Three-active bioequivalence
• Impurity profiles for each active ingredient
• Tablet dissolution across multiple strengths or presentations
• Stability under ICH conditions
• Manufacturing consistency
• Patent litigation
• Regulatory requirements for a complex fixed-dose combination

Excipient substitution can reduce cost, but it can also introduce bioequivalence and quality risk. The lowest-risk strategy is usually to preserve the functional formulation profile while using alternative grades or qualified suppliers with strong comparative data.

The most credible generic competitors are likely to be companies with established HIV portfolios, global regulatory infrastructure, and experience with complex oral solid dosage products. Potential participants include large generic manufacturers and regional firms with antiretroviral manufacturing capabilities. Actual entry timing depends on patent filings, litigation, settlement terms, and FDA approval.

What is the FDA regulatory status of Biktarvy?

Biktarvy received FDA approval in 2018 as a complete regimen for the treatment of HIV-1 infection in appropriate patients.[1] It is an oral, once-daily, fixed-dose combination tablet. The product is regulated as a small-molecule drug, not a biologic, so biosimilar pathways do not apply.

The relevant regulatory pathway for a generic version is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. An applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to FDA requirements for the product.[3]

How strong is the Biktarvy excipient estate?

The excipient estate is commercially useful but unlikely to be the primary exclusionary asset.

Dimension	Assessment
Ingredient novelty	Low
Manufacturing relevance	High
Supplier qualification burden	High
Substitution feasibility	Moderate
Independent patent strength	Generally limited
Regulatory switching cost	Moderate to high
Commercial value at scale	High
Generic design-around potential	Moderate

Biktarvy’s excipient strategy is strongest as manufacturing know-how and product-quality control. Its economic value comes from keeping a complex combination tablet stable, uniform, scalable, and acceptable to patients.

Key Takeaways

• Biktarvy uses a conventional immediate-release tablet with microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and a polyvinyl alcohol-based film coating.
• The main excipient opportunity is functional performance, not composition-of-matter exclusivity.
• Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and sodium lauryl sulfate are the highest-impact tablet-core materials.
• Ready-to-use coating systems and low-variability excipient grades are attractive supplier opportunities.
• Pediatric, dispersible, and swallowing-friendly formulations offer the clearest lifecycle-development potential.
• Generic risk depends primarily on active-ingredient, combination, product, and manufacturing patents rather than on the listed excipients.
• Biktarvy’s approximately $11.9 billion in 2023 product sales creates substantial value for supply continuity, dual sourcing, and process efficiency.
• The FDA Orange Book and litigation records must be used to determine the operative generic-entry date.

FAQs

Can a generic Biktarvy use different excipients?

Yes. A generic applicant can generally use different inactive ingredients if the product meets FDA requirements for safety, pharmaceutical equivalence, bioequivalence, quality, and performance.

Are Biktarvy’s excipients patented?

The individual excipients are established pharmaceutical materials. Any relevant patent position is more likely to concern the active-ingredient combination, drug product, manufacturing process, or formulation performance than the basic identity of the excipients.

Which Biktarvy excipient creates the greatest formulation risk?

Magnesium stearate creates significant process risk because over-lubrication can reduce tablet strength and slow dissolution. Sodium lauryl sulfate also requires careful control because surfactant level affects wetting and dissolution.

Is Biktarvy eligible for biosimilar competition?

No. Biktarvy is a small-molecule drug. A competing product would follow the generic-drug pathway, typically through an ANDA, rather than the biosimilar pathway.

What is the best commercial entry point for an excipient supplier?

The strongest entry points are qualified grades of microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and sodium lauryl sulfate, together with ready-to-use film-coating systems and dual-source supply programs.

References

1. U.S. Food and Drug Administration. (2024). Biktarvy prescribing information. Gilead Sciences, Inc.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process.
4. Gilead Sciences, Inc. (2024). 2023 annual report on Form 10-K. U.S. Securities and Exchange Commission.
5. International Council for Harmonisation. (2003). ICH Q8(R2): Pharmaceutical development.